Best of ASCO® Toronto Conference 2025: Canadian Achievements in Cancer Research – Dr. Ronan McLaughlin
NeoPancONE
GATA6 expression as a predictor of benefit to peri-operative modified FOLFIRINOX in resectable pancreatic adenocarcinoma (r-PDAC): A multicentre phase II study.
OR
[magic_login_form]
Explore more from your favourite experts – click their name to access their entire library of content.
Co-Chairs
Speakers
Studies / Trials Discussed
NeoPancONE
GATA6 expression as a predictor of benefit to peri-operative modified FOLFIRINOX in resectable pancreatic adenocarcinoma (r-PDAC): A multicentre phase II study.
This program has been made possible through unrestricted support from Johnson & Johnson.
Studies/trials discussed:
NeoPancONE
GATA6 expression as a predictor of benefit to peri-operative modified FOLFIRINOX in resectable pancreatic adenocarcinoma (r-PDAC): A multicentre phase II study.
Login to view content
PLease Enter Your Email to view Content
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.